Phaseline

Companies › 1Globe Health Institute

1Globe Health Institute: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Gastroenterology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
QX1206–Phase 1Type 2 Diabetes Mellitus (T2DM)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06694935QX1206Phase 1Type 2 Diabetes Mellitus (T2DM)GastroenterologyJul 2025

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.